Physician profile
Barry E Shibuya
NPI 1275746935
$95,622.21
in general payments reported to CMS, 2019-2025
20 companies · $6,143 in 2025
The $6,143 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,760 · 2021: $7,472 · 2022: $26K · 2023: $21K · 2024: $18K · 2025: $6,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Honoraria: $17K · Travel and Lodging: $4,209 · Food and Beverage: $4,094 · Education: $90.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,875.00 |
| Honoraria | $16,875.00 |
| Travel and Lodging | $4,208.55 |
| Food and Beverage | $4,093.52 |
| Education | $90.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $64,658.68 | 2019-2023 | Krystexxa |
| Amgen INC. | $23,212.62 | 2022-2025 | Krystexxa, Amjevita, Tavneos |
| Ucb, INC. | $1,907.53 | 2019-2024 | Cimzia |
| Abbvie INC. | $1,439.54 | 2019-2025 | Rinvoq |
| Pfizer INC. | $1,010.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $789.51 | 2019-2023 | |
| Boston Scientific Corporation | $398.92 | 2023-2025 | Bodyguardian |
| Alexion Pharmaceuticals, INC. | $312.81 | 2022-2023 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $308.60 | 2019-2022 | |
| Janssen Biotech, INC. | $290.02 | 2024-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $289.72 | 2019-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $254.76 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $138.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $104.40 | 2025 | Tremfya |
| Genzyme Corporation | $94.94 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $78.00 | 2019 | |
| Gilead Sciences, INC. | $62.72 | 2020 | |
| Genentech USA, INC. | $19.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Shibuya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.